Lucy C. Walters

Lucy C. Walters

Auto-generated profile, based on publicly available information

Lucy C. Walters

Ragon Institute of MGB, MIT and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2016 in Science
Verified
Journal Article
Closed access
PDF file
SHScott G. Hansen
Scott G. Hansen
HWHelen L. Wu
Helen L. Wu
BBBenjamin J. Burwitz
Benjamin J. Burwitz
CHColette M. Hughes
Colette M. Hughes
KHKatherine B. Hammond
Katherine B. Hammond
LPLouis J. Picker
Louis J. Picker
An unconventional route to protection: One promising approach toward an HIV-1 vaccine involves infecting people with cytomegalovirus engineered to express proteins from HIV-1. This approach, which works by eliciting virus-killing CD8 + T cells, provides robust protection in nonhuman primate models. Hansen et al. have found out why this approach is so effective. Normally, peptide antigens presented by major histocompatibility complex-1a (MHC-Ia) activate CD8 + T cells. In vaccinated monkeys, however, CD8 + T cells reacted to peptide antigens presented by MHC-E molecules instead. Moreover, MHC-E could present a much wider range of peptides than MHC-Ia. Science , this issue p. 714

29 November 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
RZReza Zonozi
Reza Zonozi
LWLucy C. Walters
Lucy C. Walters
ASAaron Shulkin
Aaron Shulkin
VNVivek Naranbhai
Vivek Naranbhai
PNPravarut Nithagon
Pravarut Nithagon
GGGaurav D. Gaiha
Gaurav D. Gaiha
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe disease and mortality from coronavirus disease 2019 (COVID-19), but the immune responses and clinical outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have yet to be fully defined. Here, we evaluate the cellular immune responses after both SARS-CoV-2 infection and vaccination in patients receiving the anti-CD20 therapy rituximab (RTX) and those with low B cell counts due to common variable immune deficiency (CVID) disease. Assessment of effector and memory CD4 + and CD8 + T cell responses to SARS-CoV-2 revealed elevated reactivity and proliferative capacity after both infection and vaccination in B cell–deficient individuals, particularly within the CD8 + T cell compartment, in comparison with healthy controls. Evaluation of clinical outcomes demonstrates that vaccination of RTX-treated individuals was associated with about 4.8-fold reduced odds of moderate or severe COVID-19 in the absence of vaccine-induced antibodies. Analysis of T cell differentiation demonstrates that RTX administration increases the relative frequency of naïve CD8 + T cells, potentially by depletion of CD8 + CD20 dim T cells, which are primarily of an effector memory or terminal effector memory (TEMRA) phenotype. However, this also leads to a reduction in preexisting antiviral T cell immunity. Collectively, these data indicate that individuals with B cell deficiencies have enhanced T cell immunity after both SARS-CoV-2 infection and vaccination that potentially accounts for reduced hospitalization and severe disease from subsequent SARS-CoV-2 infection.

14 June 2022 in Cell Reports
Verified
Journal Article
Open access
LWLucy C. Walters
Lucy C. Walters
DRDaniel Rozbesky
Daniel Rozbesky
KHKarl Harlos
Karl Harlos
MQMax Quastel
Max Quastel
HSHong Sun
Hong Sun
GGGeraldine M. Gillespie
Geraldine M. Gillespie
MHC-E regulates NK cells by displaying MHC class Ia signal peptides (VL9) to NKG2A:CD94 receptors. MHC-E can also present sequence-diverse, lower-affinity, pathogen-derived peptides to T cell receptors (TCRs) on CD8+ T cells. To understand these affinity differences, human MHC-E (HLA-E)-VL9 versus pathogen-derived peptide structures are compared. Small-angle X-ray scatter (SAXS) measures biophysical parameters in solution, allowing comparison with crystal structures. For HLA-E-VL9, there is concordance between SAXS and crystal parameters. In contrast, HLA-E-bound pathogen-derived peptides produce larger SAXS dimensions that reduce to their crystallographic dimensions only when excess peptide is supplied. Further crystallographic analysis demonstrates three amino acids, exclusive to MHC-E, that not only position VL9 close to the α2 helix, but also allow non-VL9 peptide binding with re-configuration of a key TCR-interacting α2 region. Thus, non-VL9-bound peptides introduce an alternative peptide-binding motif and surface recognition landscape, providing a likely basis for VL9- and non-VL9-HLA-E immune discrimination.

30 June 2023 in Science Immunology
Verified
Journal Article
Closed access
HYHongbing Yang
Hongbing Yang
HSHong Sun
Hong Sun
SBSimon Brackenridge
Simon Brackenridge
XZXiaodong Zhuang
Xiaodong Zhuang
PWPeter Wing
Peter Wing
AMAndrew J McMichael
Andrew J McMichael
Pathogen-specific CD8 + T cell responses restricted by the nonpolymorphic nonclassical class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections. The natural HLA-E ligand is a signal peptide derived from classical class Ia HLA molecules that interact with the NKG2/CD94 receptors to regulate natural killer cell functions, but pathogen-derived peptides can also be presented by HLA-E. Here, we describe five peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited HLA-E–restricted CD8 + T cell responses in convalescent patients with coronavirus disease 2019. These T cell responses were identified in the blood at frequencies similar to those reported for classical HLA-Ia–restricted anti–SARS-CoV-2 CD8 + T cells. HLA-E peptide–specific CD8 + T cell clones, which expressed diverse T cell receptors, suppressed SARS-CoV-2 replication in Calu-3 human lung epithelial cells. SARS-CoV-2 infection markedly down-regulated classical HLA class I expression in Calu-3 cells and primary reconstituted human airway epithelial cells, whereas HLA-E expression was not affected, enabling T cell recognition. Thus, HLA-E–restricted T cells could contribute to the control of SARS-CoV-2 infection alongside classical T cells.

1 September 2026 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TTToong Seng Tan
Toong Seng Tan
WSWeiWei Sun
WeiWei Sun
CGCe Gao
Ce Gao
MVMathias Viard
Mathias Viard
LWLucy C. Walters
Lucy C. Walters
MLMathias Lichterfeld
Mathias Lichterfeld
Host immune responses that can target and eliminate HIV-1 reservoir cells during suppressive antiretroviral therapy are poorly understood. Here, analyzing over 6,000 proviral DNA amplicons from 104 individuals on long-term antiretroviral therapy, we found that carriers of HLA-C2 allotypes, which promote NK cell education via interactions with KIR2DL1, exhibited lower frequencies of intact proviruses. No protective effects of HLA-C2 alleles were observed during untreated infection, suggesting a selective vulnerability of reservoir cells to NK-cell-mediated immune activity under antiretroviral therapy. Supporting this, frequencies of KIR2DL1 + NK cells, particularly those coexpressing the activating HLA-E receptor NKG2C, were inversely correlated with frequencies of intact proviruses. Moreover, viral protein U variants that strongly downregulate HLA-C, increasing a missing-self response by KIR2DL1 +  NK cells, were associated with smaller reservoirs in carriers of HLA-C2. Infected cells surviving long-term displayed elevated HLA-C expression, consistent with in vivo selection for resistance to KIR2DL1 +  NK-cell-mediated immune clearance. Immune activity of KIR2DL1 + NK cells against viral reservoir cells was enhanced by NKG2C–HLA-E interactions, as sequence variants in HLA-E-restricted HIV-1 epitopes reduced NKG2C-dependent NK cell activation and were associated with higher frequencies of intact proviruses. These findings underscore the critical influence of host and viral genetic variation on reservoir persistence and highlight opportunities for leveraging innate immunity in HIV cure strategies.

6 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AHAmanda C. Hornick
Amanda C. Hornick
LWLucy C. Walters
Lucy C. Walters
CDConnor S. Dobson
Connor S. Dobson
SGStephanie A. Gaglione
Stephanie A. Gaglione
MBMichael E. Birnbaum
Michael E. Birnbaum
The COVID-19 pandemic underscored the importance of rapidly analyzing antibody responses against emerging viruses. Existing techniques, however, are limited in their ability to probe antibodies’ recognition of multiple native-conformation antigens simultaneously. To increase the throughput and multiplexability of antibody profiling, we developed A ntibody R eactivity C haracterization by A ntibody- D ependent E nhancement ( ARCADE ). This assay employs an antigen-agnostic Fc receptor-expressing cell line and a library of antigen-displaying, genetically barcoded lentiviruses that, when mixed with serum, infect cells and integrate their barcodes at rates reflecting the relative abundances and affinities of the antigen-specific antibodies present. Verified using sera from COVID-19-convalescent and - vaccinated donors, ARCADE delivers insights that align with and expand upon those offered by established immunoassays, highlighting, for example, how an mRNA-based vaccine elicits broader and stronger antibody responses than an adenovirus vector-based vaccine. ARCADE can comprehensively assess how infection and vaccination impact antiviral antibody repertoires over time and across patient populations.